LUNG 6.2 (+3.33%)
US7458481014Medical Devices & InstrumentsMedical Devices

Pulmonx (LUNG) Stock Highlights

6.2 | +3.33%
2024-11-21 05:07:32
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the companys solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Statistics

Range Today
5.86 6.22
Volume Today 179.3K
Range 1 Year
5.46 14.84
Volume 1 Year 94.75M
Range 3 Year
4.07 36.37
Volume 3 Year 300.46M
Range 10 Year
4.07 69.48
Volume 10 Year 399.81M

Highlights

Market Capitalization 293.79M (small)
Floating Shares 37.82M
Current Price 6.2
Price To Earnings -5
Price To Revenue 3.05
Price To Book 3.13
Earnings Per Share -1.49
Payout Ratio 0%

Performance

Latest +3.33%
1 Month -4.47%
3 Months -7.6%
6 Months -30.57%
1 Year -42.8%
3 Years -82.12%
5 Years -84.5%
10 Years -84.5%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.